Diclofenac: A Comprehensive Pharmacological and Clinical Review

1. Introduction to Diclofenac

1.1. Overview and Summary

Diclofenac is a well-established phenylacetic acid derivative classified as a non-steroidal anti-inflammatory drug (NSAID).[1] It is primarily utilized for the management of signs and symptoms associated with various arthritic conditions, including osteoarthritis and rheumatoid arthritis.[1] Its therapeutic applications extend to ankylosing spondylitis and a range of other painful states, such as menstrual cramps (primary dysmenorrhea) and acute migraine attacks.[2] The pharmacological profile of diclofenac is characterized by its potent anti-inflammatory, analgesic (pain-relieving), and antipyretic (fever-reducing) activities.[3]

The broad spectrum of indications for diclofenac underscores its efficacy in conditions where prostaglandins play a significant pathogenic role. Prostaglandins are key mediators in inflammation, pain sensitization, and fever development. By inhibiting their synthesis, diclofenac offers relief across a diverse array of clinical scenarios. Its utility in both chronic inflammatory diseases like arthritis and acute painful conditions such as migraines highlights its versatility as a therapeutic agent.[1] This versatility is a direct consequence of its fundamental mechanism of action as an NSAID, which targets the cyclooxygenase (COX) enzymes responsible for prostaglandin production. However, this same mechanism also underpins its potential for adverse effects, particularly concerning the gastrointestinal and cardiovascular systems, which are significant enough to warrant boxed warnings from regulatory authorities like the U.S. Food and Drug Administration (FDA).[3] The widespread and long-standing use of diclofenac implies a considerable clinical impact in pain and inflammation management. Concurrently, this extensive use necessitates a comprehensive understanding and careful consideration of its risk-benefit profile in individual patients. The availability of diclofenac in multiple dosage forms—including oral, topical, and ophthalmic preparations—suggests continuous efforts within pharmaceutical development to optimize its delivery for specific conditions, enhance local effects, and potentially mitigate systemic adverse events.[2]

1.2. Historical Background and Development

The development of diclofenac was a result of rational drug design, drawing upon the chemical structures of earlier anti-inflammatory agents such as phenylbutazone, mefenamic acid, and indomethacin [User Query]. A key structural modification, the addition of two chlorine atoms at the ortho positions of the phenyl ring, is believed to lock the ring in a state of maximal torsion. This specific conformational constraint appears to be directly related to the drug's enhanced potency compared to its predecessors [User Query]. This targeted approach to drug design, aiming to improve upon existing therapies by understanding structure-activity relationships, marked an important step in pharmaceutical research and development.

Diclofenac was first granted approval by the U.S. Food and Drug Administration (FDA) in July 1988.[1] It was initially marketed under the trade name Voltaren by Ciba-Geigy.[1] The pharmaceutical company Ciba-Geigy was itself formed through the merger of Ciba and Geigy in 1970. Subsequently, in 1996, Ciba-Geigy integrated with Sandoz to form Novartis, which continues to be a major pharmaceutical entity.[8] Notably, Louis J. Ignarro, who later received the Nobel Prize in Physiology or Medicine for his work on nitric oxide, was involved in the early development of diclofenac during his tenure at Geigy Pharmaceuticals.[8]

The enduring presence of diclofenac in clinical practice for over three decades, despite the emergence of newer anti-inflammatory drugs and a greater understanding of its associated risks, attests to its perceived efficacy and established role in managing pain and inflammation. Its development through rational design, rather than serendipitous discovery, highlights a deliberate scientific effort to create a more potent NSAID. The corporate lineage from Geigy to Ciba-Geigy and ultimately to Novartis reflects common trends of consolidation and evolution within the pharmaceutical industry.

1.3. DrugBank ID, CAS Number, and Type

Diclofenac is cataloged in pharmaceutical databases with the DrugBank ID DB00586.[1] The Chemical Abstracts Service (CAS) Registry Number for diclofenac acid is 15307-86-5.[9] Chemically, diclofenac is classified as a small molecule drug.[1]

These identifiers are fundamental for the unique and unambiguous referencing of the drug substance in scientific literature, regulatory documents, and chemical databases worldwide. The CAS number ensures that diclofenac acid is precisely identified, preventing confusion with its various salt forms or related compounds. Similarly, the DrugBank ID provides a standardized reference point for accessing comprehensive curated information about the drug. The classification as a "small molecule" is typical for many orally administered pharmaceuticals developed during its era. This characteristic generally implies a capacity for chemical synthesis, straightforward formulation into various dosage forms, and potential for oral absorption and systemic distribution. Indeed, diclofenac's nature as a small molecule has facilitated its development into a wide array of pharmaceutical preparations, including tablets, capsules, topical gels, patches, and ophthalmic solutions, catering to diverse therapeutic needs.[2]

2. Chemical and Physical Properties

The chemical and physical properties of diclofenac are crucial for understanding its behavior as a pharmaceutical agent, including its formulation, absorption, distribution, and interaction with biological systems. Diclofenac is primarily available as the free acid or as its sodium or potassium salts.

2.1. IUPAC Name and Synonyms

The International Union of Pure and Applied Chemistry (IUPAC) name for diclofenac acid is 2-[(2,6-dichlorophenyl)amino]phenyl]acetic acid.[1] It is also referred to as [2-(2,6-dichloroanilino)phenyl]acetic acid [1] or 2-((2,6-Dichlorophenyl)amino)benzeneacetic acid.[9]

Diclofenac is the International Nonproprietary Name (INN).[9] Common synonyms for the acid form include diclofenac acid, diclofenaco, and diclofenacum.[1] Brand names associated with diclofenac, often referring to its salt forms, include Voltaren® and Cataflam®.[11] The existence of numerous synonyms and brand names reflects its extensive clinical application and global marketing. The core phenylacetic acid structure is shared by several NSAIDs, indicating a common chemical class, while the specific 2,6-dichloroanilino substitution confers diclofenac its distinct potency, largely due to the conformational restriction imposed by the ortho-chlorine atoms, as noted in its developmental background [User Query].

2.2. Molecular Formula and Weight

The molecular formula for diclofenac acid is C14​H11​Cl2​NO2​.1

Its average molecular weight is approximately 296.15 g/mol 1, with a monoisotopic mass of 295.016684015 Da.1

Diclofenac is also commonly formulated as salts:

• Diclofenac Sodium: Molecular formula C14​H10​Cl2​NNaO2​, with a molecular weight of 318.13 g/mol.[14]
• Diclofenac Potassium: Molecular formula C14​H10​Cl2​KNO2​, with a molecular weight of 334.24 g/mol.[15]

The molecular weight aligns with its classification as a small molecule, which typically facilitates oral absorption and allows for diverse formulation strategies. The use of different salt forms (sodium, potassium) is a common pharmaceutical approach to enhance properties such as solubility or dissolution rate. For instance, diclofenac potassium is often employed in immediate-release formulations like Cataflam® or Cambia® (powder for oral solution), where rapid absorption is desired for acute conditions such as pain or migraine.[2] In contrast, diclofenac sodium is frequently used in enteric-coated or delayed-release tablets, such as Voltaren®, for chronic conditions like arthritis, where sustained release and protection of the gastric mucosa are important considerations.[2] This choice of salt form is a deliberate pharmaceutical strategy to tailor the drug's pharmacokinetic profile to specific therapeutic objectives.

2.3. Appearance

Diclofenac acid is typically described as a white powder 11 or a white to slightly yellow crystalline powder.16

Diclofenac sodium appears as a white solid 14 or a white to almost white powder.14

This crystalline powder form is characteristic of many solid pharmaceutical substances, facilitating easier handling, processing, and incorporation into various dosage forms like tablets and capsules. The appearance, including color and form, serves as an important quality control parameter in pharmaceutical manufacturing. Any significant deviations could indicate the presence of impurities or degradation products, which would necessitate further investigation. The consistent description across sources suggests well-established purity standards for pharmaceutical-grade diclofenac.

2.4. Solubility

The solubility of diclofenac varies depending on whether it is in its acid or salt form, and on the pH of the solvent:

• Diclofenac Acid: It has limited solubility in water, reported as 237 mg/L (or 0.237 mg/mL).[11] Its carboxylic acid group can form hydrogen bonds with water, but the bulky, hydrophobic chlorinated phenyl groups can impede full dissolution in aqueous media. It is generally more soluble in non-polar to slightly polar organic solvents.[16]
• Diclofenac Sodium: This salt form exhibits significantly greater water solubility, reported as 50 mg/mL.[14]
• Diclofenac Potassium: The potassium salt is described as being slightly soluble in water under acidic pH conditions, with its solubility increasing as the pH rises towards 7.5.[15]

The poor aqueous solubility of diclofenac acid presents a common challenge in pharmaceutical formulation, often addressed by utilizing its more soluble salt forms. The enhanced water solubility of the sodium and potassium salts generally leads to faster dissolution rates in the gastrointestinal tract, which can translate to quicker absorption and onset of action compared to the free acid. This property is particularly leveraged in formulations like Cambia® (diclofenac potassium for oral solution), designed for rapid relief of acute migraine pain.[12] Solubility characteristics are a primary determinant of a drug's bioavailability from oral dosage forms and heavily influence formulation strategies, such as the use of enteric coatings to protect the drug from the acidic environment of the stomach and to target its release in the more neutral pH of the intestine.

2.5. Melting Point

The melting points reported for diclofenac and its sodium salt are:

• Diclofenac Acid: 156-158 °C.[11]
• Diclofenac Sodium: 283-285 °C [18] or 288-290 °C.[14] A sharp melting peak at 285 °C for diclofenac sodium has also been noted in thermal analysis studies.[19]

The significantly higher melting point of the sodium salt compared to the free acid is typical and suggests stronger intermolecular forces within its crystal lattice, contributing to its stability as a solid. A well-defined melting point is a key indicator of purity and is routinely used for quality control in pharmaceutical manufacturing. While a high melting point generally indicates good thermal stability, which is advantageous for storage and processing, it has been observed that diclofenac sodium may undergo degradation at or near its melting temperature during certain analytical procedures like Differential Scanning Calorimetry (DSC).[19] Despite this, diclofenac sodium's thermal stability is considered sufficient for processes like hot-melt extrusion (HME) [19], though careful control of temperature and exposure time is crucial to prevent degradation during such manufacturing steps.

2.6. pKa

The pKa value for diclofenac is reported as 4.0 (at 25°C).[14] This value reflects the acidity of the carboxylic acid group (COOH) present in the diclofenac molecule.

A pKa of 4.0 indicates that diclofenac is a weak acid. This characteristic is common among many NSAIDs that feature a carboxylic acid moiety. The pKa value is critical as it determines the extent to which the drug will be ionized at different physiological pH values. This ionization state, in turn, profoundly influences its solubility, absorption across biological membranes, distribution into tissues, and pathways of excretion. For instance, in the highly acidic environment of the stomach (pH ≈ 1-2), where the pH is below its pKa, diclofenac will exist predominantly in its non-ionized, more lipid-soluble form. This form is generally favored for passive diffusion across cell membranes. However, the low solubility of the free acid in acidic conditions might limit its dissolution rate.[15] Conversely, in the more neutral to slightly alkaline environment of the small intestine (pH ≈ 6-7.4), where the pH is above its pKa, diclofenac will be primarily in its ionized, more water-soluble form. While ionization enhances solubility, it can reduce passive membrane permeability. This interplay between pKa, pH, ionization, and solubility is fundamental to understanding the oral absorption kinetics of diclofenac and provides the rationale for formulation strategies such as enteric coating. Enteric-coated tablets are designed to bypass the acidic stomach and release diclofenac in the intestine, where the higher pH facilitates dissolution of the salt form, allowing for subsequent absorption.

2.7. Stability

Diclofenac sodium is generally described as stable.[14] Specific studies on compounded oral suspensions of diclofenac sodium (10 mg/mL prepared from tablets using Ora-Blend® as a vehicle) demonstrated excellent stability. These suspensions retained at least 99.5% of their initial concentration for up to 93 days when stored at either room temperature (23°C) or under refrigeration (5°C), with no significant changes in physical appearance, odor, or pH.[20] This robust stability in suspension is valuable for extemporaneous compounding in pharmacies, particularly when liquid dosage forms are required.

Regarding thermal stability, diclofenac sodium has been reported to exhibit high stability under elevated processing temperatures, making it a suitable candidate for advanced manufacturing techniques such as hot-melt extrusion (HME).[19] However, thermogravimetric analysis (TGA) has indicated potential degradation pathways at very high temperatures, with weight losses corresponding to dehydration (below 110°C), oxidation (230-410°C), and pyrolysis (above 450°C).[19] Furthermore, during Differential Scanning Calorimetry (DSC), degradation of diclofenac sodium was observed around its melting point (285°C).[19]

This nuanced thermal stability profile suggests that while diclofenac sodium is robust enough for controlled thermal processing like HME (where heat exposure may be transient or conditions precisely managed), prolonged exposure to extreme temperatures, especially near its melting point, can lead to degradation. This distinction is critical for pharmaceutical technologists in designing manufacturing processes and for analytical chemists in selecting appropriate testing conditions. The good stability observed in aqueous suspensions also indicates that diclofenac does not readily undergo hydrolysis or oxidation under normal storage conditions in such formulations.

Table 1: Key Chemical and Physical Properties of Diclofenac Acid and Diclofenac Sodium

Property	Diclofenac Acid	Diclofenac Sodium	Reference(s)
IUPAC Name	2-[2-[(2,6-dichlorophenyl)amino]phenyl]acetic acid	Sodium 2-[2-[(2,6-dichlorophenyl)amino]phenyl]acetate	1
Molecular Formula	C14​H11​Cl2​NO2​	C14​H10​Cl2​NNaO2​	1
Molecular Weight	296.15 g/mol	318.13 g/mol	1
Appearance	White to slightly yellow crystalline powder	White solid / White to Almost white powder	11
Water Solubility	237 mg/L (0.237 mg/mL)	50 mg/mL	11
Melting Point	156-158 °C	283-290 °C	11
pKa	4.0 (at 25°C)	N/A (salt of weak acid)	17
Stability	Generally stable; specific data for acid form limited	Stable; suspensions stable for 93 days at RT/refrigerated	14

This table provides a consolidated view of the essential physicochemical properties, highlighting the differences between the acid and sodium salt forms, which are critical for formulation and understanding bioavailability.

3. Pharmacology

The pharmacological actions of diclofenac underpin its therapeutic efficacy in treating pain and inflammation. Its effects are primarily mediated through the inhibition of prostaglandin synthesis, though other minor mechanisms may also contribute.

3.1. Mechanism of Action

3.1.1. Inhibition of Cyclooxygenase (COX-1 and COX-2)

Diclofenac exerts its primary pharmacological effect by inhibiting the cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2.[1] These enzymes are critical for the conversion of arachidonic acid into various prostaglandins (PGs), which are key mediators of inflammation, pain, and fever.[1] Diclofenac is a potent inhibitor of prostaglandin synthesis in vitro, and the concentrations achieved during therapy are sufficient to produce these inhibitory effects in vivo.[5] The inhibition of COX enzymes by diclofenac is competitive with respect to the arachidonic acid substrate.[4]

The selectivity of diclofenac for COX-1 versus COX-2 has been a subject of some discussion. While generally classified as a non-selective NSAID [23], some evidence suggests a degree of preference for COX-2. For instance, it has been reported to exhibit approximately four times greater inhibition of COX-2 than COX-1 in vitro, a level of selectivity comparable to that of celecoxib.[4] However, other reported IC50 values (0.9-2.7 µM for human COX-1 and 1.5-20 µM for human COX-2) might suggest non-selectivity or even a slight preference for COX-1, depending on the specific assay conditions and isoforms tested.[17] Regulatory bodies like the European Medicines Agency (EMA) note that traditional NSAIDs, including diclofenac, act by blocking both COX-1 and COX-2.[25] The clinical implication of this nuanced selectivity profile, particularly the cardiovascular risk assessment by the EMA which aligns diclofenac's risk with that of selective COX-2 inhibitors at high doses [25], suggests that its in vivo impact may functionally resemble that of agents with significant COX-2 inhibition.

3.1.2. Impact on Prostaglandin Synthesis Pathways

By inhibiting COX-1 and COX-2, diclofenac effectively reduces the synthesis of various prostanoids, including prostaglandin E2 (PGE2), prostacyclin (PGI2), and thromboxanes (e.g., TXA2).[4] Prostaglandins play a crucial role in sensitizing afferent nerves to painful stimuli and potentiating the pain-inducing effects of other mediators like bradykinin. They are also pivotal mediators of the inflammatory response, contributing to vasodilation, increased vascular permeability, and leukocyte infiltration.[5] Diclofenac has been noted as one of the most effective inhibitors of PGE2 production, a prostaglandin particularly important in inflammation and pain signaling.[4] This reduction in prostaglandin levels at sites of inflammation and injury is the cornerstone of diclofenac's therapeutic effects.

3.1.3. Other Relevant Pharmacological Actions

Beyond its primary action on COX enzymes, other mechanisms have been proposed to contribute to diclofenac's overall pharmacological profile, although these are generally considered secondary. These putative actions include the inhibition of leukotriene synthesis, reduction of phospholipase A2 activity (which would decrease the availability of arachidonic acid, the substrate for COX enzymes), and modulation of free arachidonic acid levels.[17] Additionally, stimulation of ATP-sensitive potassium channels via the L-arginine-nitric oxide-cyclic guanosine monophosphate pathway has been suggested.[17] There is also evidence that diclofenac may reduce elevated levels of substance P, a pro-inflammatory and nociceptive neuropeptide, in the synovial fluid of patients with rheumatoid arthritis.[4] While these additional mechanisms are less well-established than COX inhibition, they could potentially contribute to the drug's efficacy in certain contexts.

The balance between COX-1 and COX-2 inhibition is critical. COX-1 is constitutively expressed in many tissues and is responsible for producing prostaglandins involved in physiological "housekeeping" functions, such as gastric cytoprotection, maintenance of renal blood flow, and platelet aggregation. Inhibition of COX-1 is largely responsible for the common gastrointestinal side effects of NSAIDs. COX-2, on the other hand, is primarily an inducible enzyme, upregulated at sites of inflammation and injury, producing prostaglandins that mediate pain and inflammation. The nuanced COX inhibition profile of diclofenac, potentially with a greater effect on COX-2 than some other traditional NSAIDs but still retaining significant COX-1 inhibition, contributes to its therapeutic efficacy as well as its specific adverse effect profile, including both gastrointestinal and cardiovascular risks. The EMA's assessment linking diclofenac's cardiovascular risk profile to that of selective COX-2 inhibitors, especially at high doses and with long-term use [25], highlights the clinical significance of its impact on the COX pathway, regardless of precise in vitro selectivity ratios. This has led to more stringent regulatory warnings and contraindications in certain patient populations.

3.2. Pharmacodynamics

The pharmacodynamic effects of diclofenac—anti-inflammatory, analgesic, and antipyretic—are direct consequences of its primary mechanism of action: the inhibition of prostaglandin synthesis.[3] By reducing the production of prostaglandins, diclofenac modulates key pathological processes.

• Anti-inflammatory effect: Prostaglandins are potent mediators of inflammation, causing vasodilation, increased vascular permeability, and promoting the influx of inflammatory cells. By inhibiting their synthesis, diclofenac reduces these cardinal signs of inflammation, such as swelling, redness, warmth, and pain.[5]
• Analgesic effect: Prostaglandins, particularly PGE2, sensitize peripheral nociceptors (pain receptors) to mechanical stimuli and to other chemical mediators of pain like bradykinin and histamine. Diclofenac's inhibition of prostaglandin synthesis raises the pain threshold and reduces pain perception both at the site of inflammation and potentially through central mechanisms.[5] Its peripheral analgesic effects may also involve the stimulation of the L-arginine nitric oxide cGMP pathway, leading to decreased availability of sensitized peripheral pain receptors.[4]
• Antipyretic effect: Fever is often mediated by prostaglandins (especially PGE2) produced in the hypothalamus in response to pyrogenic stimuli. Diclofenac can reduce fever by inhibiting hypothalamic prostaglandin synthesis, thereby resetting the thermoregulatory set point.

The potency of these pharmacodynamic effects makes diclofenac an effective drug for a wide range of conditions. However, the very mechanism that confers these benefits—the inhibition of prostaglandin synthesis—also leads to its characteristic adverse effects. Prostaglandins are involved in many vital physiological functions, including protecting the gastric mucosa, maintaining renal blood flow and glomerular filtration rate, and modulating platelet function. Interference with these prostaglandin-mediated processes can result in gastrointestinal ulceration and bleeding, renal dysfunction, and an increased risk of bleeding. This intrinsic link between efficacy and toxicity is a fundamental challenge with all NSAIDs, and diclofenac is no exception.

3.3. Pharmacokinetics

The pharmacokinetic profile of diclofenac describes its absorption, distribution, metabolism, and excretion (ADME), which collectively determine the onset, intensity, and duration of its pharmacological effects.

3.3.1. Absorption

Diclofenac is well absorbed following oral administration, with approximately 100% of the dose absorbed when compared to intravenous (IV) administration, as determined by urinary recovery of metabolites.[3] However, it undergoes significant first-pass hepatic metabolism, which reduces its systemic bioavailability to about 50-55%.[3]

The presence of food does not significantly alter the extent of diclofenac absorption from standard enteric-coated or immediate-release tablets. However, food typically delays the onset of absorption by 1 to 4.5 hours and may reduce peak plasma concentrations (Cmax​) by less than 20%.[3] For immediate-release diclofenac potassium tablets (e.g., Cataflam®), peak plasma levels are generally achieved in approximately 1 hour in fasting individuals.[6] For certain formulations, such as Zorvolex® (diclofenac free acid capsules) and Cambia® (diclofenac potassium for oral solution), taking the medication with food may reduce its effectiveness compared to administration on an empty stomach.[12]

Topical formulations, such as the Flector® Patch, result in systemic absorption, with peak plasma concentrations of diclofenac ranging from 0.7 to 6 ng/mL observed between 10 to 20 hours after a single application.[27] The systemic bioavailability from Solaraze® Gel (diclofenac sodium 3%) is considerably lower than that achieved with oral dosing.[22] Ophthalmic administration is also expected to result in minimal systemic absorption. This difference in systemic exposure between oral and topical/ophthalmic routes is a key factor in the differing risk profiles.

3.3.2. Distribution

The apparent volume of distribution (V/F) for diclofenac is approximately 1.3 to 1.4 L/kg.[3] Diclofenac is extensively bound to human serum proteins, exceeding 99%, with albumin being the primary binding protein.[3] This high degree of protein binding is constant over the therapeutic concentration range and limits the amount of free, pharmacologically active drug in circulation.

A significant characteristic of diclofenac's distribution is its ability to penetrate synovial fluid. It diffuses into and out of the joints; initially, when plasma levels are higher, it moves into the synovial fluid, and later, as plasma levels decline, synovial fluid concentrations can exceed those in the plasma.[3] This preferential distribution to and persistence in inflamed tissues like the synovium is highly relevant to its efficacy in treating arthritic conditions.[21]

3.3.3. Metabolism

Diclofenac undergoes extensive hepatic metabolism, which accounts for almost 100% of its elimination.[3] The two major metabolic pathways are acyl glucuronidation of the parent drug and hydroxylation of the phenyl rings followed by glucuronidation or sulfation of the hydroxylated metabolites.[1]

Five principal metabolites have been identified in human plasma and urine: 4'-hydroxy-, 5-hydroxy-, 3'-hydroxy-, 4',5-dihydroxy-, and 3'-hydroxy-4'-methoxy diclofenac.[3] The 4'-hydroxy-diclofenac metabolite is quantitatively the most important hydroxylation product [24] but possesses very weak pharmacological activity.[3]

Several cytochrome P450 (CYP) enzymes are involved in the oxidative metabolism of diclofenac. CYP2C9 is primarily responsible for the formation of 4'-hydroxy-diclofenac.[1] CYP3A4 is involved in the 5-hydroxylation and can exhibit cooperative kinetics, particularly in the presence of certain modulators like quinidine.[1] There is also evidence that CYP2C8 may contribute to further hydroxylation of diclofenac glucuronide.[1] The acyl glucuronidation of diclofenac itself is primarily catalyzed by UDP-glucuronosyltransferase (UGT) 2B7.[1]

Importantly, the metabolism of diclofenac can also lead to the formation of reactive electrophilic intermediates, specifically diclofenac 1',4'- and 2,5-quinone imines. These reactive metabolites are capable of forming covalent adducts with proteins and have been implicated in the mechanism of diclofenac-induced hepatotoxicity.[1]

3.3.4. Excretion

Diclofenac is eliminated from the body primarily through metabolic transformation followed by the excretion of its metabolites, mainly as glucuronide and sulfate conjugates.[3] Approximately 65% of an administered dose is excreted in the urine, and about 35% is eliminated in the bile (feces).[3] Less than 1% of the dose is excreted as unchanged diclofenac in the urine.[3]

The terminal elimination half-life of unchanged diclofenac is relatively short, reported to be in the range of 1.1 to 2.3 hours.[3] This short half-life necessitates multiple daily dosing for immediate-release formulations to maintain therapeutic drug concentrations for chronic conditions, or the use of extended-release preparations.

The pharmacokinetic profile of diclofenac, particularly its extensive metabolism via CYP2C9, has significant clinical implications. CYP2C9 is a genetically polymorphic enzyme, meaning that variations in the CYP2C9 gene can lead to substantial inter-individual differences in enzyme activity. Individuals who are CYP2C9 poor metabolizers will clear diclofenac more slowly, resulting in higher plasma concentrations and prolonged exposure from a standard dose. This increased exposure can elevate the risk of dose-dependent adverse effects, including gastrointestinal toxicity, cardiovascular events, and renal complications. Similarly, co-administration of diclofenac with potent inhibitors of CYP2C9 (e.g., voriconazole, fluconazole, amiodarone) can mimic the poor metabolizer phenotype by reducing diclofenac clearance, thereby increasing systemic exposure and the potential for toxicity.[6] Conversely, co-administration with CYP2C9 inducers (e.g., rifampin) could decrease diclofenac plasma concentrations and potentially compromise its efficacy.[6] These factors underscore the importance of considering potential drug-drug interactions and, in some contexts, the potential influence of pharmacogenetics on diclofenac therapy. The formation of reactive metabolites, linked to CYP-mediated oxidation, is a critical factor contributing to the risk of idiosyncratic drug-induced liver injury (DILI), a rare but serious adverse effect associated with diclofenac.[29]

Table 2: Summary of Diclofenac Pharmacokinetic Parameters (Oral Administration)

Parameter	Value	Reference(s)
Oral Bioavailability	~50-55% (due to first-pass metabolism)	3
Tmax (oral immediate-release)	~1 hour (fasting)	6
Protein Binding	>99% (primarily to albumin)	3
Volume of Distribution (V/F)	1.3 - 1.4 L/kg	3
Metabolism	Extensive hepatic; acyl glucuronidation (UGT2B7), hydroxylation (CYP2C9, CYP3A4, CYP2C8)	1
Key Metabolites	4'-hydroxy-, 5-hydroxy-, 3'-hydroxy-diclofenac, etc. (4'-OH is a major, weakly active metabolite)	3
Elimination Half-life	~1.1 - 2.3 hours	3
Excretion	~65% urine, ~35% bile (as conjugates); <1% unchanged in urine	3

This table summarizes key pharmacokinetic parameters, providing a quick reference for understanding how diclofenac behaves in the body.

4. Clinical Applications

Diclofenac is utilized across a spectrum of clinical conditions, primarily for its anti-inflammatory and analgesic properties. Its applications are supported by approvals from regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), as well as through off-label uses based on clinical experience and evidence.

4.1. Approved Therapeutic Indications

4.1.1. FDA-Approved Indications

The FDA has approved various formulations of diclofenac for several indications:

• Oral Formulations (e.g., Voltaren®, Cataflam®, Zorvolex®, Zipsor®, Cambia®):
• Relief of the signs and symptoms of osteoarthritis.[1]
• Relief of the signs and symptoms of rheumatoid arthritis.[1]
• Acute or long-term use for the relief of signs and symptoms of ankylosing spondylitis.[1]
• Treatment of primary dysmenorrhea (menstrual cramps) (Cataflam®).[6]
• Relief of mild to moderate pain (Cataflam®, Zipsor®, Zorvolex®).[6]
• Acute treatment of migraine attacks with or without aura in adults (Cambia® - diclofenac potassium for oral solution).[2]
• Topical Formulations (e.g., Voltaren® Gel, Pennsaid®, Flector® Patch, Solaraze® Gel):
• Voltaren® Arthritis Pain Gel (diclofenac sodium topical gel 1%): For the temporary relief of arthritis pain in the hand, wrist, elbow, foot, ankle, or knee.[35]
• Pennsaid® (diclofenac sodium topical solution 1.5% and 2%): For the treatment of the signs and symptoms (1.5%) or pain (2%) of osteoarthritis of the knee(s).[37]
• Flector® Patch (diclofenac epolamine topical patch 1.3%): For the topical treatment of acute pain due to minor strains, sprains, and contusions.[27]
• Solaraze® Gel (diclofenac sodium topical gel 3%): For the topical treatment of actinic keratoses (AK).[4]
• Ophthalmic Formulation (Voltaren® Ophthalmic):
• Treatment of postoperative inflammation in patients who have undergone cataract extraction.[4]
• Temporary relief of pain and photophobia in patients undergoing corneal refractive surgery.[4]

The availability of these diverse formulations allows for targeted therapy. For example, topical preparations aim to deliver the drug locally to affected joints or skin lesions, thereby minimizing systemic exposure and potentially reducing the risk of systemic adverse effects associated with oral NSAIDs. This strategy is particularly relevant for conditions like localized osteoarthritis. Similarly, the ophthalmic solution provides targeted anti-inflammatory action within the eye. The development of a rapid-acting oral solution (Cambia®) for migraine underscores formulation efforts to meet the specific needs of acute conditions requiring quick onset of relief.

4.1.2. EMA-Approved Indications

In Europe, diclofenac (systemic formulations) is broadly authorized for the relief of pain and inflammation associated with a wide range of conditions, including arthritic disorders and acute musculoskeletal problems.23

Topical formulations, such as Diclofenac 1% Gel, are indicated for adults and adolescents aged 14 years and older for the treatment of mild to moderate muscle pain, contusions, and post-traumatic pain.44

The EMA's regulatory oversight has particularly focused on the cardiovascular risks associated with systemic diclofenac, leading to updated recommendations and contraindications to align its risk profile with that of selective COX-2 inhibitors.23 This highlights a cautious approach to its systemic use, especially in patients with pre-existing cardiovascular conditions.

4.1.3. Off-label Uses

In addition to FDA and EMA-approved indications, diclofenac has been used off-label for various conditions, including:

• Biliary colic [4]
• Corneal abrasion [4]
• Fever [4]
• Gout (beyond acute migraine, for gouty arthritis attacks) [4]
• Myalgia (muscle pain) [4]
• Post-episiotomy pain [4]
• Juvenile Idiopathic Arthritis (JIA) for oral formulations.[45]

The existence of off-label uses reflects the drug's long history and broad anti-inflammatory and analgesic effects, leading clinicians to explore its utility in conditions beyond formal approvals. However, such use should always be based on careful clinical judgment and consideration of available evidence.

The development and approval of numerous diclofenac formulations tailored for specific indications—from systemic conditions like rheumatoid arthritis to localized issues like knee osteoarthritis (topical) or post-cataract surgery inflammation (ophthalmic)—illustrates a clear pharmaceutical strategy. This strategy aims to maximize therapeutic efficacy at the target site while minimizing systemic drug exposure and the consequent risk of adverse events. This is particularly pertinent given the known systemic risks of NSAIDs. The EMA's heightened scrutiny of systemic diclofenac's cardiovascular safety profile further emphasizes the trend towards favoring localized therapies or alternative agents for patients at higher risk.

4.2. Dosage Forms and Strengths

Diclofenac is available in a wide array of dosage forms and strengths, reflecting its broad clinical utility and efforts to optimize delivery for different indications and patient needs. The active moiety may be diclofenac acid or one of its salts (sodium, potassium, epolamine). It is critical to note that different formulations, even with similar milligram strengths of diclofenac, may not be bioequivalent and are often not interchangeable.[12]

Table 3: Summary of Common Diclofenac Formulations, Strengths, and Key U.S. Brand Names

Dosage Form	Active Ingredient(s)	Strength(s)	Key Brand Name(s) (U.S.)	Primary Use Type	Reference(s)
Enteric-coated/Delayed-Rel. Tab	Diclofenac Sodium	25 mg, 50 mg, 75 mg	Voltaren®, various generics	Systemic (Chronic)	2
Extended-Release Tablet	Diclofenac Sodium	100 mg	Voltaren® XR, various generics	Systemic (Chronic)	2
Immediate-Release Tablet	Diclofenac Potassium	50 mg	Cataflam®, Lofena®	Systemic (Acute/Chronic)	2
Capsule (Liquid Filled)	Diclofenac Potassium	25 mg	Zipsor®	Systemic (Acute Pain)	2
Capsule	Diclofenac (free acid)	18 mg, 35 mg	Zorvolex®	Systemic (Acute/OA Pain)	2
Powder for Oral Solution	Diclofenac Potassium	50 mg/packet	Cambia®	Systemic (Migraine)	2
Topical Gel	Diclofenac Sodium	1%	Voltaren® Arthritis Pain	Topical (OA Pain)	35
Topical Gel	Diclofenac Sodium	3%	Solaraze®	Topical (Actinic Keratosis)	40
Topical Solution	Diclofenac Sodium	1.5%, 2%	Pennsaid®	Topical (OA Knee Pain)	37
Topical Patch	Diclofenac Epolamine	1.3% (180 mg or 182 mg/patch)	Flector®, Licart®	Topical (Acute Pain)	1
Ophthalmic Solution	Diclofenac Sodium	0.1%	Voltaren® Ophthalmic	Ophthalmic	42
IV Injection	Diclofenac Sodium	37.5 mg/mL	Dyloject®	Systemic (Acute Pain)	31

The extensive variety of available formulations underscores the pharmaceutical industry's efforts to tailor diclofenac delivery for specific clinical scenarios. This includes optimizing for rapid onset (e.g., Cambia® for migraine), sustained release for chronic conditions (e.g., Voltaren® XR), localized delivery to minimize systemic exposure (e.g., Voltaren® Gel, Pennsaid®, Flector® Patch), or specialized application (e.g., Solaraze® for actinic keratosis, Voltaren® Ophthalmic). The physicochemical properties of diclofenac, such as the differing solubilities of its acid and salt forms (see Section 2.4), directly influence these formulation strategies. For instance, the higher solubility of diclofenac potassium facilitates its use in rapid-acting oral solutions. The non-interchangeability of certain oral formulations, such as Zorvolex® (diclofenac free acid) with diclofenac salt products [26], or Cambia® oral solution with tablets [12], is a critical consideration for prescribers and pharmacists. This is because different salt forms or specialized formulation technologies (e.g., SoluMatrix Fine Particle Technology™ used for Zorvolex®) can result in distinct pharmacokinetic profiles, including absorption rates and overall bioavailability, potentially leading to under- or over-dosing if substitutions are made without appropriate consideration.

4.3. Dosage Regimens for Key Indications

Dosage regimens for diclofenac must be individualized based on the specific indication, the formulation chosen, patient response, and tolerability. A guiding principle across all formulations is to use the lowest effective dose for the shortest duration necessary to achieve treatment goals and minimize adverse effects.[3]

• Osteoarthritis (Oral):
• Diclofenac sodium enteric-coated tablets: 50 mg two or three times daily, or 75 mg twice daily. Maximum daily dose is typically 150 mg.[2]
• Diclofenac sodium extended-release tablets: 100 mg once daily.[2]
• Diclofenac free acid capsules (Zorvolex®): 35 mg three times daily.[2]
• Osteoarthritis (Topical):
• Voltaren® Arthritis Pain Gel 1%: For upper extremities (hand, wrist, elbow), apply 2 grams four times daily. For lower extremities (foot, ankle, knee), apply 4 grams four times daily. Total daily dose over all affected joints should not exceed 32 grams.[35]
• Pennsaid® 2% topical solution: Apply 2 pump actuations (40 mg diclofenac sodium) to each affected knee twice daily.[38]
• Pennsaid® 1.5% topical solution: Apply 40 drops per affected knee four times daily.[37]
• Rheumatoid Arthritis (Oral):
• Diclofenac sodium enteric-coated tablets: 50 mg three to four times daily, or 75 mg twice daily. Recommended daily dose is 150-200 mg.[2] Maximum daily dose up to 225 mg for diclofenac sodium tablets has been mentioned, but labels often cite 200mg as upper for RA.[31]
• Diclofenac sodium extended-release tablets: 100 mg once daily. May be increased to 100 mg twice daily in rare instances where benefits outweigh risks.[31]
• Ankylosing Spondylitis (Oral):
• Diclofenac sodium enteric-coated tablets: 25 mg four times daily, with an additional 25 mg dose at bedtime if necessary. Maximum daily dose is 125 mg.[2]
• Acute Pain (Oral):
• Diclofenac potassium liquid-filled capsules (Zipsor® 25 mg): 25 mg four times daily.[2]
• Diclofenac free acid capsules (Zorvolex® 18 mg or 35 mg): 18 mg or 35 mg three times daily.[2]
• Diclofenac potassium immediate-release tablets: 50 mg three times daily. An initial dose of 100 mg may be given for some patients.[2]
• Acute Pain (Topical Flector® Patch):
• Apply one (1.3%) patch to the most painful area twice daily.[39]
• Acute Pain (IV Dyloject®):
• 37.5 mg administered as an IV bolus over 15 seconds, every 6 hours as needed for pain. Maximum daily dose is 150 mg. Patients should be well hydrated prior to IV administration.[31]
• Migraine (Oral Cambia®):
• One 50 mg packet (diclofenac potassium for oral solution) mixed in 1 to 2 ounces (30 to 60 mL) of water, taken as a single dose for the acute treatment of migraine. Not indicated for prophylactic therapy.[2]
• Actinic Keratosis (Topical Solaraze® 3% Gel):
• Apply to the affected skin area(s) twice daily.[40]
• Postoperative Ocular Inflammation (Voltaren® Ophthalmic 0.1% Solution):
• Instill one drop into the affected eye four times daily, beginning 24 hours after cataract surgery and continuing for the first 2 weeks of the postoperative period.[42]
• Pain and Photophobia in Corneal Refractive Surgery (Voltaren® Ophthalmic 0.1% Solution):
• Instill one or two drops into the operative eye within the hour prior to corneal refractive surgery. Within 15 minutes after surgery, instill one or two drops into the operative eye. Then, continue with one or two drops into the operative eye four times daily for up to 3 days as needed.[42]

The short elimination half-life of diclofenac (approximately 1.1 to 2.3 hours, see Section 3.3.4) underpins the need for multiple daily doses for most immediate-release oral formulations to maintain therapeutic drug levels. The development of extended-release tablets is a direct pharmaceutical response to this pharmacokinetic characteristic, aiming to improve patient compliance by reducing dosing frequency and providing more stable plasma concentrations over the dosing interval. The variety of formulations and their specific, often non-interchangeable, dosing regimens necessitate careful attention from healthcare providers to prevent medication errors and ensure optimal therapeutic outcomes while minimizing risks.

5. Safety Profile

The safety profile of diclofenac is a critical aspect of its clinical use, characterized by potential risks common to NSAIDs, particularly concerning the cardiovascular and gastrointestinal systems. These risks have led to specific contraindications, FDA boxed warnings, and detailed precautions.

5.1. Contraindications

Diclofenac is contraindicated in several specific patient populations and clinical situations due to an unacceptable risk of adverse events:

• Hypersensitivity: Patients with known hypersensitivity to diclofenac or any of its formulation components should not use the drug.[3]
• Aspirin/NSAID-Induced Allergic Reactions: Patients who have experienced asthma, urticaria (hives), or other allergic-type reactions after taking aspirin or other NSAIDs are contraindicated. Severe, sometimes fatal, anaphylactic reactions have been reported in such individuals.[3]
• Coronary Artery Bypass Graft (CABG) Surgery: Diclofenac is contraindicated for the treatment of perioperative pain in the setting of CABG surgery due to an increased risk of myocardial infarction and stroke.[3]
• Specific Formulation Contraindications:
• Zipsor® (diclofenac potassium liquid-filled capsules) is contraindicated in patients with known hypersensitivity to bovine protein, as the capsules contain gelatin.[33]
• Solaraze® Gel (diclofenac sodium 3% topical gel) is contraindicated for application to damaged or non-intact skin, including areas affected by exudative dermatitis, eczema, infected lesions, burns, or wounds.[41]
• Additional Contraindications (Primarily for Systemic Formulations, often reflecting EMA guidance):
• Active gastric or intestinal ulcer, bleeding, or perforation.[48]
• Last trimester of pregnancy.[48]
• Hepatic failure.[48]
• Renal failure (specifically defined as Glomerular Filtration Rate <15 mL/min/1.73m²).[48]
• Severe cardiac failure (e.g., New York Heart Association [NYHA] class II-IV, depending on specific labeling).[48]
• Established ischemic heart disease, peripheral arterial disease, and/or cerebrovascular disease (these are particularly emphasized by EMA for systemic diclofenac).[25]

The contraindications highlight the primary areas of concern: allergic potential (especially cross-reactivity within the NSAID class), acute cardiovascular settings like CABG, active severe gastrointestinal pathology, and significant organ impairment. The evolution of cardiovascular contraindications, particularly by European regulatory authorities to include a broader range of established cardiovascular diseases for systemic diclofenac, reflects an increasing understanding of NSAID-associated cardiovascular risk and a more cautious approach to its use in vulnerable populations. This necessitates that clinicians remain updated on the most current and stringent guidelines pertinent to their region to ensure patient safety.

5.2. FDA Boxed Warnings

The FDA mandates boxed warnings for diclofenac products, underscoring the most serious potential risks associated with its use. These warnings are consistent across systemic formulations and are also included on the labeling for most topical formulations, reflecting the potential for systemic absorption and risk, albeit generally lower with topical use.

• Cardiovascular Thrombotic Events: NSAIDs, including diclofenac, cause an increased risk of serious and potentially fatal cardiovascular thrombotic events, such as myocardial infarction (heart attack) and stroke. This risk may manifest early in the course of treatment and can increase with the duration of use. Patients with pre-existing cardiovascular disease or identifiable risk factors for cardiovascular disease may be at greater risk. As noted in contraindications, diclofenac is specifically contraindicated for perioperative pain management in the context of CABG surgery.3
• Gastrointestinal Bleeding, Ulceration, and Perforation: NSAIDs, including diclofenac, cause an increased risk of serious gastrointestinal (GI) adverse events. These include inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, any of which can be fatal. These severe GI events can occur at any point during therapy and may do so without preceding warning symptoms. Elderly patients and individuals with a prior history of peptic ulcer disease or GI bleeding are at a significantly higher risk for these complications.3

The consistent presence of these boxed warnings across nearly all diclofenac formulations emphasizes the gravity of these potential adverse outcomes. While the absolute risk from topical formulations is generally lower due to reduced systemic absorption compared to oral administration, the potential for systemic effects means these warnings remain relevant. The cardiovascular risk is thought to be related to an imbalance in vasoactive prostaglandins (e.g., inhibition of cardioprotective prostacyclin [PGI2], primarily COX-2 derived, without a proportional decrease in prothrombotic thromboxane A2, primarily COX-1 derived). Gastrointestinal toxicity is largely attributed to the inhibition of COX-1, which is responsible for producing prostaglandins that protect the gastric mucosa.

5.3. Common and Serious Adverse Drug Reactions by System Organ Class

Diclofenac can cause a range of adverse drug reactions (ADRs), varying in frequency and severity. Many of these are class effects shared with other NSAIDs.

• Gastrointestinal System:
• Common: Abdominal pain, constipation, diarrhea, dyspepsia (indigestion), flatulence, heartburn, nausea, vomiting.[3] Application site reactions (e.g., dermatitis, pruritus) are common with topical gel.[35]
• Serious: Gross bleeding/perforation, GI ulcers (gastric/duodenal).[3] Less frequently, esophagitis, gastritis, glossitis (tongue inflammation), hematemesis (vomiting blood), pancreatitis, colitis.[3] NSAIDs are associated with an increased risk of gastro-intestinal anastomotic leak after GI surgery.[49]
• Cardiovascular System:
• Common: Edema (fluid retention).[3]
• Serious: Myocardial infarction, stroke, new onset or worsening of hypertension, congestive heart failure, tachycardia, syncope.[3] Arrhythmia, hypotension, palpitations, vasculitis (rarely).[3] Kounis syndrome (allergic acute coronary syndrome) has been reported.[49]
• Hepatic System:
• Common: Elevated liver enzymes (transaminases, ALT, AST).[3] These elevations are often borderline and may be transient but can progress.
• Serious: Drug-induced hepatotoxicity, hepatitis (sometimes without prodromal symptoms), jaundice, liver failure, liver necrosis (rarely, but can be fatal or require transplantation).[3] Periodic monitoring of liver function is recommended during long-term therapy.[3]
• Renal and Urinary System:
• Common: Abnormal renal function.[3]
• Serious: Acute kidney injury, renal papillary necrosis, interstitial nephritis, nephrotic syndrome, renal failure, hematuria (blood in urine), proteinuria (protein in urine), hyperkalemia.[3] Caution is advised in patients with impaired renal function, heart failure, liver dysfunction, dehydration, or those taking diuretics or ACE inhibitors, and in the elderly.[48]
• Hematologic System:
• Common: Anemia (possibly due to GI blood loss or fluid retention), increased bleeding time.[3]
• Serious: Ecchymosis (bruising), eosinophilia, leukopenia (low white blood cell count), melena (black, tarry stools), purpura, rectal bleeding, thrombocytopenia (low platelet count).[3] Rarely, agranulocytosis, hemolytic anemia, aplastic anemia, lymphadenopathy, pancytopenia.[3] Diclofenac may temporarily inhibit platelet aggregation.[48]
• Nervous System:
• Common: Dizziness, headache.[3] Somnolence with some formulations like Zipsor®.[33]
• Serious: Anxiety, asthenia (weakness), confusion, depression, dream abnormalities, drowsiness, insomnia, malaise, nervousness, paresthesia (numbness/tingling), tremors, vertigo.[3] Rarely, convulsions, coma, hallucinations, meningitis.[3]
• Respiratory System:
• Common: None consistently reported as common across all labels.
• Serious: Asthma, dyspnea (shortness of breath).[3] Exacerbation of asthma, particularly in aspirin-sensitive individuals.[48] Rarely, respiratory depression, pneumonia.[3]
• Dermatologic/Hypersensitivity Reactions:
• Common (topical application): Application site reactions such as dermatitis, pruritus (itching), erythema (redness), dryness, rash, vesicles (blisters), irritation, papules.[35]
• Common (systemic): Pruritus, rashes.[3]
• Serious: Anaphylactic/anaphylactoid reactions (can occur without prior exposure), angioedema, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), exfoliative dermatitis, erythema multiforme, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).[3] Photosensitivity.[3]
• Special Senses:
• Common: Tinnitus (ringing in the ears).[3] With ophthalmic use: transient burning/stinging, keratitis, elevated intraocular pressure, lacrimation.[42]
• Serious: Blurred vision.[3] Rarely, conjunctivitis, hearing impairment.[3] With ophthalmic use: corneal erosion, infiltrates, perforation, thinning, ulceration, epithelial breakdown.[42]
• Metabolic and Nutritional:
• Common: Weight changes (not consistently reported as common).[3]
• Serious: Rarely, hyperglycemia.[3]
• Body as a Whole:
• Common: None consistently reported as common for systemic use.
• Serious: Fever, infection, sepsis.[3] Rarely, appetite changes, death.[3]

The risk of these adverse reactions, particularly serious GI, CV, and renal events, tends to be dose-dependent and increases with the duration of use. Elderly patients are generally at higher risk for many of these serious adverse events.[3] The development of topical formulations aims to reduce systemic exposure and thereby mitigate some of these systemic risks, but vigilance is still required.

6. Drug Interactions

Diclofenac has the potential to interact with numerous other medications, which can alter its efficacy or safety, or that of the co-administered drugs. These interactions often stem from its pharmacokinetic properties (e.g., high protein binding, CYP450 metabolism) and its pharmacodynamic effects (e.g., inhibition of prostaglandin synthesis, effects on platelet function).

• Anticoagulants (e.g., Warfarin): Concomitant use of diclofenac and anticoagulants like warfarin significantly increases the risk of serious bleeding, particularly gastrointestinal bleeding, due to a synergistic effect. Close monitoring of INR and for signs of bleeding is crucial if co-administration is unavoidable.[1]
• Antiplatelet Agents (e.g., Aspirin, Clopidogrel): Similar to anticoagulants, combining diclofenac with antiplatelet agents (including low-dose aspirin used for cardiovascular prophylaxis) elevates the risk of bleeding and hemorrhage.[1] The FDA label for Voltaren advises against concomitant use of diclofenac and aspirin generally due to increased adverse effects.[3]
• Other NSAIDs and Salicylates: Co-administration with other NSAIDs or salicylates is generally not recommended. It increases the risk of gastrointestinal toxicity (ulceration, bleeding) with little to no additive therapeutic benefit.[1]
• Corticosteroids (e.g., Prednisone): The combined use of diclofenac and systemic corticosteroids may potentiate the risk of serious gastrointestinal toxicity, including ulceration and bleeding. Caution is advised, especially in high-risk patients.[1]
• ACE Inhibitors (e.g., Lisinopril) and Angiotensin II Receptor Blockers (ARBs) (e.g., Losartan): NSAIDs, including diclofenac, may diminish the antihypertensive effect of ACE inhibitors and ARBs. In elderly, volume-depleted, or renally impaired patients, concomitant use can increase the risk of renal function deterioration, including acute renal failure. Blood pressure and renal function should be monitored.[1]
• Diuretics (e.g., Furosemide, Hydrochlorothiazide): Diclofenac can reduce the natriuretic and antihypertensive effects of loop diuretics (like furosemide) and thiazide diuretics. This is attributed to the inhibition of renal prostaglandin synthesis. Patients on diuretics may be at increased risk of renal failure if NSAIDs are co-administered, and diuretic efficacy should be monitored.[1] The "triple whammy" combination of an NSAID, a diuretic, and an ACE inhibitor or ARB is particularly associated with an increased risk of acute kidney injury.[60]
• Lithium: NSAIDs can elevate plasma lithium levels and reduce its renal clearance by inhibiting renal prostaglandin synthesis. Patients receiving diclofenac and lithium concurrently should be closely monitored for signs of lithium toxicity.[1]
• Methotrexate: Concurrent use of NSAIDs with methotrexate may increase methotrexate plasma levels and its toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction) by competitively inhibiting its renal tubular secretion. Caution and monitoring are required.[1]
• Cyclosporine: Concomitant administration of diclofenac and cyclosporine may increase cyclosporine's nephrotoxicity, possibly due to effects on renal prostaglandins. Renal function should be monitored.[1]
• Digoxin: Diclofenac has been reported to increase serum concentrations and prolong the half-life of digoxin. Serum digoxin levels should be monitored if these drugs are used together.[1]
• Selective Serotonin Reuptake Inhibitors (SSRIs) / Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) (e.g., Fluoxetine, Sertraline, Venlafaxine): Co-administration of diclofenac with SSRIs or SNRIs may potentiate the risk of bleeding, particularly gastrointestinal bleeding, as these agents can affect platelet function.[1]
• CYP2C9 Inhibitors (e.g., Voriconazole, Fluconazole): Since diclofenac is primarily metabolized by CYP2C9, co-administration with potent CYP2C9 inhibitors can significantly increase diclofenac exposure and the risk of toxicity. Dosage adjustment of diclofenac may be warranted.[6]
• CYP2C9 Inducers (e.g., Rifampin): Co-administration with CYP2C9 inducers may decrease diclofenac plasma concentrations and potentially reduce its efficacy. Dosage adjustment may be needed.[6]

Effects on Laboratory Tests

Diclofenac therapy can influence the results of certain laboratory tests:

• Liver Function Tests: Elevations in serum aminotransferases (ALT, AST) are relatively common during diclofenac therapy. Meaningful elevations (e.g., >3 times the upper limit of normal) can occur. Regular monitoring of liver function is recommended during long-term treatment.[3]
• Renal Function Tests: NSAIDs can affect renal function; monitoring parameters like serum creatinine and BUN may be necessary, especially in at-risk patients or during long-term use.[3]
• Complete Blood Count (CBC): Anemia can occur with NSAID use. Hemoglobin and hematocrit should be checked in patients on long-term therapy if they exhibit signs or symptoms of anemia or blood loss.[3]
• Bleeding Time: Diclofenac can inhibit platelet aggregation and may prolong bleeding time, although this effect is generally transient and less pronounced than with aspirin.[3]

It is important for clinicians to be aware that diclofenac itself is not typically screened for in standard narcotic or illicit drug tests and will not cause a false positive for such substances.[65]

7. Use in Special Populations

The use of diclofenac requires careful consideration in specific patient populations due to potential alterations in pharmacokinetics, increased susceptibility to adverse effects, or specific risks.

7.1. Pregnancy

• FDA Recommendations & Risks: The U.S. Food and Drug Administration (FDA) advises against the use of NSAIDs, including diclofenac, starting at week 20 of pregnancy, unless specifically recommended by a healthcare provider, due to the risk of oligohydramnios (low amniotic fluid) secondary to fetal renal dysfunction. Use should be avoided particularly in the third trimester (from week 30 onwards) because NSAIDs can cause premature closure of the fetal ductus arteriosus.[3] If NSAID treatment is deemed necessary between 20 and 30 weeks of gestation, it should be limited to the lowest effective dose and shortest duration possible, and ultrasound monitoring for oligohydramnios should be considered if treatment extends beyond 48 hours.[56]
• Diclofenac is classified as Pregnancy Category C by older FDA systems, meaning animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.[3] However, this categorization is being phased out in favor of more descriptive risk summaries.
• Reproduction studies in animals have not consistently shown teratogenicity, but maternal and fetal toxicity (e.g., dystocia, prolonged gestation, reduced fetal weight and survival) have been observed at maternally toxic doses.[3] Diclofenac is known to cross the placental barrier.[3]
• Some studies have suggested a possible increased risk of miscarriage with NSAID use early in pregnancy, but this association is not definitively established and may be confounded by the underlying reasons for NSAID use.[66]
• Formulations of diclofenac combined with misoprostol (e.g., Arthrotec®) are contraindicated in pregnant women due to the abortifacient properties of misoprostol.[4]

7.2. Lactation

• Excretion in Breast Milk and Safety: Diclofenac is excreted into breast milk in small amounts.[3] However, the levels detected in breast milk are generally very low, often below measurable quantities with typical maternal doses.[35]
• Most experts and organizations, including the American Academy of Pediatrics [70], consider diclofenac compatible with breastfeeding due to this minimal transfer and lack of reported adverse effects in breastfed infants when used at standard therapeutic doses.[69]
• Topical or ophthalmic application of diclofenac is expected to result in even lower systemic absorption by the mother and, consequently, negligible amounts in breast milk.[66]
• Caution is generally advised: if a topical product is applied to or near the breast, the area should be washed before breastfeeding to avoid direct infant contact.[70] Mothers should monitor infants for any unusual symptoms such as vomiting or diarrhea, although these are unlikely to be related to diclofenac exposure through breast milk.[70]

7.3. Pediatric Use

• Approved Indications and Age Restrictions:
• Oral Formulations: Diclofenac tablets, capsules, and suppositories can be prescribed for children from 12 months of age for juvenile idiopathic arthritis (JIA) or other arthritic conditions.[71] However, specific FDA-approved labeling for products like Voltaren® states that safety and effectiveness in pediatric patients have not been established.[3] Off-label use for JIA is noted.[45] Some sources suggest diclofenac can be given to pediatric patients aged 6 years and older, with dose adjustments based on weight.[72] Zipsor® (diclofenac potassium liquid-filled capsules) is indicated for acute pain in children 12 years of age and older.[2]
• Topical Gel (e.g., Voltaren Gel): Can be used by adolescents aged 14 years and older.[71]
• Topical Plasters/Patches (e.g., Flector Patch): Can be used by adolescents aged 16 years and older.[71] Flector Patch is specifically indicated for acute pain due to minor strains, sprains, and contusions in pediatric patients 6 years and older.[73]
• Ophthalmic Solution (Voltaren Ophthalmic): Safety and effectiveness in pediatric patients have not been established.[42]
• Specific Dosing: For children older than 3 years, a general oral dose of 2-3 mg/kg/day has been suggested for up to one month.[74] For children aged 12 to 16 years (45-55 kg), oral diclofenac 25 mg can be recommended up to three or four times a day; for children aged 9 to 11 years (35-44 kg), up to three times a day.[75] Pharmacokinetic meta-analyses have aimed to recommend doses for children aged 1-12 years (e.g., 0.3 mg/kg IV, 0.5 mg/kg suppository, 1 mg/kg oral) to achieve similar exposure to adults.[72] The lowest effective dose for the shortest duration is crucial.[72]
• The variability in age restrictions and dosing recommendations across different sources and product labels highlights the need for careful, product-specific prescribing in children. Actinic keratosis, an indication for Solaraze® Gel, is not a condition typically seen in the pediatric population.[67]

7.4. Geriatric Use

• Increased Risks and Dosing Considerations: Elderly patients (typically defined as 65 years and older) are generally at a greater risk for NSAID-associated adverse effects, particularly serious cardiovascular events (myocardial infarction, stroke), gastrointestinal events (ulceration, bleeding, perforation), and renal toxicity.[2]
• While studies have not always demonstrated geriatric-specific problems that would limit the usefulness of diclofenac, increased caution is warranted.[2]
• Dose selection in the elderly should be cautious, usually starting at the lower end of the dosing range, reflecting the higher frequency of decreased hepatic, renal, or cardiac function, and the greater likelihood of concomitant diseases or other drug therapies.[34]
• Diclofenac and its metabolites are substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function. Since elderly patients are more likely to have decreased renal function, careful dose selection and monitoring of renal function may be useful.[2]
• Specific product labels like Zorvolex® advise starting treatment at the lowest dose in elderly patients with hepatic insufficiency.[78] Pennsaid® (topical solution) labeling also suggests caution and potential dose adjustment due to increased likelihood of age-related kidney, heart, or stomach problems.[40]
• Diclofenac is included on the Beers Criteria list as a medication to be potentially avoided or used with caution in older adults due to these increased risks.[4]

The use of diclofenac in these special populations necessitates a thorough assessment of the potential benefits versus the risks. For pregnant women, especially in the latter half of pregnancy, avoidance is generally recommended. During lactation, diclofenac appears to be relatively safe due to low transfer into breast milk. Pediatric use is restricted for certain formulations and requires careful dosing. In geriatric patients, the heightened risk of serious adverse events mandates a cautious approach, starting with lower doses and diligent monitoring.

8. Regulatory Information

8.1. FDA Approval History and Status

Diclofenac, in its various forms, has a long history of approval by the U.S. Food and Drug Administration (FDA).

• Initial Approval (Voltaren®): Diclofenac sodium, under the brand name Voltaren®, was first approved by the FDA on July 28, 1988. The original applicant was Ciba-Geigy Corporation (now part of Novartis).[1]
• Subsequent Formulations: Over the years, numerous other diclofenac-containing products and formulations have received FDA approval, including:
• Cataflam® (diclofenac potassium immediate-release tablets).[6]
• Voltaren® Gel 1% (diclofenac sodium topical gel), initially approved as a prescription product on October 17, 2007, for osteoarthritis pain. On February 14, 2020, its status was changed to over-the-counter (OTC) and marketed as Voltaren® Arthritis Pain.[81]
• Zipsor® (diclofenac potassium liquid-filled capsules) for mild to moderate acute pain.[33]
• Zorvolex® (diclofenac capsules, containing diclofenac free acid) for mild to moderate acute pain and osteoarthritis pain, with initial U.S. approval in 1988 (referring to diclofenac generally) and Zorvolex specific approvals later (e.g., label from 2013/2021).[26]
• Pennsaid® (diclofenac sodium topical solution, 1.5% and 2%) for osteoarthritis of the knee(s).[37]
• Flector® Patch (diclofenac epolamine topical system 1.3%) for acute pain due to minor strains, sprains, and contusions.[27]
• Solaraze® Gel (diclofenac sodium topical gel 3%) for actinic keratoses.[22]
• Cambia® (diclofenac potassium for oral solution) for acute treatment of migraine.[12]
• Voltaren® Ophthalmic (diclofenac sodium ophthalmic solution 0.1%) for postoperative ocular inflammation and pain/photophobia after corneal refractive surgery.[42]
• Dyloject® (diclofenac sodium injection) for intravenous administration for pain management.[31]

All FDA-approved diclofenac products carry boxed warnings regarding cardiovascular and gastrointestinal risks.[3] The availability of an OTC formulation (Voltaren Arthritis Pain) signifies a regulatory assessment that, for specific indications and at specific concentrations with appropriate labeling, the benefit-risk profile is acceptable for self-medication by consumers.

8.2. EMA Regulatory Status

In the European Union, diclofenac-containing medicinal products are authorized at the national level by individual Member States and have been available for many years under various trade names.[25] Systemic formulations (e.g., oral, injectable) are generally authorized for the relief of pain and inflammation in a wide range of conditions, including arthritic conditions and acute musculoskeletal disorders.[23] Topical formulations are also available, for example, for mild to moderate muscle pain and contusions.[44]

The European Medicines Agency (EMA) has conducted reviews of the safety of diclofenac, particularly concerning its cardiovascular risks. In 2013, following a review by the Pharmacovigilance Risk Assessment Committee (PRAC), the EMA concluded that the cardiovascular risks of systemic diclofenac (especially when used at high doses, e.g., 150 mg daily, and for long-term treatment) are similar to those of selective COX-2 inhibitors.[23] This led to updated recommendations and harmonized product information across the EU, including:

• Contraindication in patients with established congestive heart failure (NYHA class II-IV), ischemic heart disease, peripheral arterial disease, or cerebrovascular disease.[25]
• Recommendation that patients with significant risk factors for cardiovascular events (e.g., hypertension, hyperlipidemia, diabetes mellitus, smoking) should only be treated with diclofenac after careful consideration.[25]
• Emphasis on using the lowest effective daily dose for the shortest possible duration.[25] Topical formulations were generally not included in the scope of these specific cardiovascular risk reviews due to their low systemic exposure, which is considered unlikely to pose significant systemic risks.[23] The EMA's actions reflect an ongoing process of pharmacovigilance and risk management for widely used medicines.

8.3. Common Brand Names and Manufacturers

Diclofenac is marketed globally under numerous brand names. Some of the common brand names available, particularly in the U.S. and Europe, include:

• Voltaren® (diclofenac sodium/epolamine - various formulations including tablets, gel, ophthalmic solution) - Originator Ciba-Geigy, now Novartis; GSK Consumer Healthcare for OTC gel.[1]
• Cataflam® (diclofenac potassium immediate-release tablets) - Novartis.[1]
• Zipsor® (diclofenac potassium liquid-filled capsules).[1]
• Zorvolex® (diclofenac free acid capsules).[1]
• Pennsaid® (diclofenac sodium topical solution) - Horizon Therapeutics USA, Inc. (a U.S. example).[1]
• Flector® Patch (diclofenac epolamine topical system).[1]
• Licart® (diclofenac epolamine topical system).[1]
• Solaraze® Gel (diclofenac sodium topical gel 3%).[1]
• Cambia® (diclofenac potassium for oral solution).[1]
• Dyloject® (diclofenac sodium injection).[31]
• Other European brand names include Dicloflex®, Diclomax®, Econac®, Motifene®.[82]

Numerous generic manufacturers also produce diclofenac products worldwide. Companies like AdvaCare Pharma and Elam Pharma are examples of manufacturers and suppliers of diclofenac active pharmaceutical ingredients (API) and finished formulations.[85] The original development is linked to Geigy, later Ciba-Geigy, which became part of Novartis.[1]

9. Overdosage

Overdosage with diclofenac, as with other NSAIDs, can occur, although severe toxicity is more common with large ingestions.

9.1. Symptoms and Toxicity

Symptoms following acute NSAID overdoses are generally limited to [1]:

• Lethargy
• Drowsiness
• Nausea and vomiting (common)
• Epigastric pain (stomach pain)
• Diarrhea

More severe symptoms or complications can include [1]:

• Gastrointestinal bleeding: This can manifest as bloody or black, tarry stools, or vomiting of blood or material that looks like coffee grounds.
• Hypertension (high blood pressure) or, less commonly, hypotension (low blood pressure).
• Acute renal failure: Little or no urine output can be a sign.
• Respiratory depression: Slow, shallow, or irregular breathing.
• Central Nervous System effects: Dizziness, headache, confusion, agitation, blurred vision, ringing in the ears (tinnitus). In very severe overdoses, seizures or coma (decreased level of consciousness) may occur.
• Metabolic acidosis (in severe overdose).
• Chest pain and increased heart rate.
• Edema (swelling).

The toxicity of diclofenac can be influenced by factors such as the amount ingested and individual patient characteristics, including pre-existing conditions and variations in drug metabolism (e.g., cytochrome P450 polymorphisms).[4] Large overdoses can be particularly harmful in both children and adults.[88]

9.2. Management of Overdose

There is no specific antidote for diclofenac (or other NSAID) toxicity.[4] Management of overdose is primarily supportive and symptomatic, focusing on maintaining vital functions and addressing complications.[1] Key management strategies include:

• Airway, Breathing, and Circulation (ABCs): Ensure a patent airway, adequate breathing, and circulatory support. This may include oxygen, IV fluids, and, in severe cases, mechanical ventilation.[88]
• Decontamination:
• Activated Charcoal: If ingestion is recent (ideally within 1-2 hours, though some benefit may be seen up to 4 hours), administration of activated charcoal (typically 1 g/kg) can help reduce absorption of the drug from the GI tract.[1]
• Emesis (inducing vomiting) or Gastric Lavage: Generally not recommended for NSAID overdose due to the rapid absorption and risk of aspiration, unless a very large, potentially life-threatening amount was ingested very recently and the patient is fully conscious with protected airways. This decision should be guided by poison control or emergency medical personnel.[88]
• Supportive Care:
• Fluid and Electrolyte Balance: IV fluids may be necessary to maintain hydration and correct electrolyte imbalances.
• Monitoring: Vital signs (temperature, pulse, respiration, blood pressure), renal function (urine output, creatinine, electrolytes), liver function, and mental status should be closely monitored.[88] Blood and urine tests, chest X-ray, and ECG may be performed.[88]
• Gastrointestinal Protection: If GI bleeding is suspected or confirmed, endoscopy may be required to identify and treat the source of bleeding. Medications to reduce stomach acid (e.g., proton pump inhibitors or H2 blockers) may be used.[88]
• Seizures: If seizures occur, they should be treated with appropriate anticonvulsant medication (e.g., benzodiazepines).
• Hypotension: May require IV fluids and, if severe, vasopressors.
• Renal Failure: Management of acute renal failure may include fluid management and, in severe cases, dialysis. However, due to high protein binding, diclofenac itself is not effectively removed by hemodialysis.[88]
• Enhanced Elimination: Forced diuresis, alkalinization of urine, hemodialysis, or hemoperfusion are generally not considered effective in enhancing the elimination of diclofenac due to its high degree of protein binding.[1]

Patients should be observed for several hours post-ingestion, as symptoms may be delayed. Consultation with a poison control center is highly recommended for guidance on management.[88] The prognosis depends on the amount ingested and the promptness and adequacy of treatment. While mild overdoses usually resolve with supportive care, large ingestions can lead to severe complications, including permanent kidney damage or death.[88]

10. Conclusion and Key Considerations for Clinical Practice

Diclofenac is a potent non-steroidal anti-inflammatory drug with well-established analgesic, anti-inflammatory, and antipyretic properties. Its efficacy in managing a wide spectrum of conditions, from chronic arthritic diseases like osteoarthritis and rheumatoid arthritis to acute pain states such as migraines and postoperative pain, has solidified its place in clinical practice for several decades. The rational design underpinning its development aimed for enhanced potency, a characteristic that contributes to its therapeutic effectiveness.

The pharmacological action of diclofenac is primarily mediated through the inhibition of cyclooxygenase (COX-1 and COX-2) enzymes, leading to a reduction in prostaglandin synthesis. While generally considered non-selective, discussions regarding its relative COX-2 selectivity persist, with some evidence suggesting a profile that, particularly at higher doses, aligns its cardiovascular risk with that of more selective COX-2 inhibitors. This has prompted significant regulatory attention and has led to more stringent warnings and contraindications, especially from European authorities.

The pharmacokinetic profile of diclofenac is characterized by good oral absorption (though subject to first-pass metabolism), high protein binding, extensive hepatic metabolism (predominantly via CYP2C9), and a relatively short elimination half-life. These characteristics have several clinical implications:

• The short half-life necessitates multiple daily dosing for immediate-release oral forms or the use of extended-release formulations for sustained therapeutic effects in chronic conditions.
• The significant role of CYP2C9 in its metabolism highlights the potential for drug-drug interactions with CYP2C9 inhibitors or inducers, and for inter-individual variability in response and toxicity due to genetic polymorphisms in this enzyme.
• The formation of reactive metabolites during its hepatic metabolism is believed to contribute to its potential for idiosyncratic hepatotoxicity.

The development of a diverse array of dosage forms—including oral tablets (immediate, delayed, and extended-release), capsules, powders for oral solution, topical gels, solutions, patches, and ophthalmic preparations—reflects a concerted effort to optimize diclofenac therapy. Topical and ophthalmic formulations, in particular, aim to provide localized therapeutic effects while minimizing systemic exposure and the associated risks of adverse events. This strategy is especially valuable for conditions amenable to local treatment, such as osteoarthritis of specific joints or postoperative ocular inflammation, and in patients at higher risk from systemic NSAID exposure.

Despite its efficacy, the use of diclofenac is associated with significant safety concerns, prominently highlighted by FDA boxed warnings regarding cardiovascular thrombotic events and serious gastrointestinal bleeding, ulceration, and perforation. Other important risks include hepatotoxicity, renal toxicity, hypersensitivity reactions, and adverse effects in special populations.

Key considerations for clinical practice include:

• Individualized Risk-Benefit Assessment: Before initiating diclofenac, a thorough assessment of the patient's cardiovascular, gastrointestinal, renal, and hepatic risk factors is paramount. The potential benefits must be carefully weighed against these risks.
• Lowest Effective Dose for Shortest Duration: This principle should guide all prescribing decisions to minimize dose- and duration-dependent adverse effects.
• Formulation Selection: The choice of formulation should be tailored to the specific indication, desired onset and duration of action, and the goal of minimizing systemic exposure where appropriate (e.g., using topical formulations for localized musculoskeletal pain). Awareness of the non-interchangeability of certain oral formulations is crucial to prevent dosing errors.
• Patient Counseling: Patients should be educated about the potential risks, symptoms of serious adverse events (e.g., signs of GI bleed, heart attack, stroke, liver problems), and the importance of adhering to the prescribed dosage and duration. They should also be advised to report any concerning symptoms promptly.
• Monitoring: For patients on long-term therapy, periodic monitoring of blood pressure, renal function, liver function tests, and complete blood count may be appropriate.
• Drug Interactions: Clinicians must be vigilant about potential drug interactions, particularly with anticoagulants, antiplatelet agents, other NSAIDs, corticosteroids, ACE inhibitors, ARBs, diuretics, lithium, methotrexate, and cyclosporine, as well as drugs affecting CYP2C9 activity.
• Special Populations: Particular caution is required when considering diclofenac for elderly patients, those with pre-existing organ impairment, and pregnant or lactating women, with specific contraindications and precautions applying.

In conclusion, diclofenac remains a valuable therapeutic option for many patients suffering from pain and inflammation. However, its use demands a comprehensive understanding of its pharmacological profile, a careful evaluation of individual patient risks, and adherence to best practice guidelines to maximize benefits while minimizing potential harm. The evolving regulatory landscape and ongoing research continue to refine its place in therapy, emphasizing a cautious and informed approach to its prescription and use.

Works cited

1. Diclofenac: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed June 4, 2025, https://go.drugbank.com/drugs/DB00586
2. Diclofenac (oral route) - Mayo Clinic, accessed June 4, 2025, https://www.mayoclinic.org/drugs-supplements/diclofenac-oral-route/description/drg-20069748
3. www.accessdata.fda.gov, accessed June 4, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019201s038lbl.pdf
4. Diclofenac - StatPearls - NCBI Bookshelf, accessed June 4, 2025, https://www.ncbi.nlm.nih.gov/books/NBK557879/
5. VOLTAREN - accessdata.fda.gov, accessed June 4, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019201s046lbl.pdf
6. www.accessdata.fda.gov, accessed June 4, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020142s021s022lbl.pdf
7. Diclofenac Sodium - Drug Targets, Indications, Patents - Patsnap Synapse, accessed June 4, 2025, https://synapse.patsnap.com/drug/a1bd813e5a4f4ace888eabddf7fb0eae
8. Three paths to Novartis - American Chemical Society, accessed June 4, 2025, http://pubs.acs.org/subscribe/archive/mdd/v07/i03/pdf/304timeline.pdf
9. Diclofenac [USAN:INN:BAN] - PubChem, accessed June 4, 2025, https://pubchem.ncbi.nlm.nih.gov/substance/134992838
10. 2-(2,6-Dichloroanilino)phenylacetic Acid 15307-86-5 - TCI Chemicals, accessed June 4, 2025, https://www.tcichemicals.com/US/en/p/D3748
11. Diclofenac acid - CAS-Number 15307-86-5 - Order from Chemodex, accessed June 4, 2025, https://www.chemodex.com/products/diclofenac-acid/
12. Diclofenac Oral Solution: Package Insert / Prescribing Info - Drugs.com, accessed June 4, 2025, https://www.drugs.com/pro/diclofenac-oral-solution.html
13. diclofenac | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed June 4, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2714
14. 15307-79-6(Diclofenac sodium) Product Description - ChemicalBook, accessed June 4, 2025, https://www.chemicalbook.com/ChemicalProductProperty_US_CB5474464.aspx
15. CHEMISTRY REVIEW(S) - accessdata.fda.gov, accessed June 4, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022165Orig1s000ChemR.pdf
16. Diclofenac - Solubility of Things, accessed June 4, 2025, https://www.solubilityofthings.com/2-36-dichloro-2-methoxy-phenylacetic-acid
17. Diclofenac sodium | 15307-79-6 - ChemicalBook, accessed June 4, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5474464.htm
18. Diclofenac, accessed June 4, 2025, https://www.drugfuture.com/chemdata/diclofenac.html
19. Thermal Behaviour of Diclofenac Sodium: Decomposition and Melting Characteristics., accessed June 4, 2025, https://www.researchgate.net/publication/11744204_Thermal_Behaviour_of_Diclofenac_Sodium_Decomposition_and_Melting_Characteristics
20. pmc.ncbi.nlm.nih.gov, accessed June 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2832562/#:~:text=The%20diclofenac%20sodium%20suspensions%20were,days%2C%20regardless%20of%20storage%20temperature.
21. Stability of Diclofenac Sodium Oral Suspensions Packaged in Amber Polyvinyl Chloride Bottles, accessed June 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2832562/
22. SOLARAZE GEL Rx Only FOR DERMATOLOGIC USE ONLY. NOT FOR OPHTHALMIC USE. DESCRIPTION Solaraze (diclofenac sodium) Gel, 3%, co - accessdata.fda.gov, accessed June 4, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021005s013lbl.pdf
23. Diclofenac - EMA, accessed June 4, 2025, https://www.ema.europa.eu/system/files/documents/referral/wc500134475_en.pdf
24. Diclofenac Pathway, Pharmacokinetics - PharmGKB, accessed June 4, 2025, https://www.pharmgkb.org/pathway/PA166163705
25. Diclofenac-containing medicines - referral | European Medicines Agency (EMA), accessed June 4, 2025, https://www.ema.europa.eu/en/medicines/human/referrals/diclofenac-containing-medicines
26. This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed June 4, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/204592s013lbl.pdf
27. FLECTOR - diclofenac epolamine patch - accessdata.fda.gov, accessed June 4, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021234s006s007lbl.pdf
28. DICLOFENAC: A Review on Its Synthesis, Mechanism of Action, Pharmacokinetics, Prospect and Environmental Impact, accessed June 4, 2025, https://mjpms.uomus.edu.iq/mjpms/vol2/iss3/2/
29. The Metabolism of Diclofenac - Enzymology and Toxicology Perspectives - EurekaSelect, accessed June 4, 2025, https://eurekaselect.com/public/article/8414
30. The Metabolism of Diclofenac - Enzymology and Toxicology Perspectives - ResearchGate, accessed June 4, 2025, https://www.researchgate.net/publication/10653703_The_Metabolism_of_Diclofenac_-_Enzymology_and_Toxicology_Perspectives
31. Diclofenac Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed June 4, 2025, https://www.drugs.com/dosage/diclofenac.html
32. Cataflam Label - accessdata.fda.gov, accessed June 4, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020142s017lbl.pdf
33. ZIPSOR ® (diclofenac potassium) is a prescription Non-Steroidal Anti-Inflammatory Drug (NSAID). ZIPSOR is used for relief of mild-to-moderate pain in adults (18 years of age and older)., accessed June 4, 2025, https://www.zipsor.com/hcp/
34. www.accessdata.fda.gov, accessed June 4, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204592s000lbl.pdf
35. DICLOFENAC SODIUM- diclofenac sodium topical gel, 1 ... - DailyMed, accessed June 4, 2025, https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aee20924-79ab-400e-b9b6-418978914654
36. Voltaren Arthritis Pain: Package Insert / Prescribing Info - Drugs.com, accessed June 4, 2025, https://www.drugs.com/pro/voltaren-arthritis-pain.html
37. PENNSAID (diclofenac sodium) topical solution - accessdata.fda.gov, accessed June 4, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020947s010s011lbl.pdf
38. Pennsaid PA with Limit 787-C 07-2022 - Specialty Pharmacy Clinical Policy Bulletins Aetna Non-Medicare Prescription Drug Plan, accessed June 4, 2025, https://www.aetna.com/products/rxnonmedicare/data/2025/Pennsaid_PA_with_Limit_787-C_07-2022.html
39. Flector Patch (diclofenac epolamine) label - accessdata.fda.gov, accessed June 4, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021234s005lbl.pdf
40. Diclofenac (topical application route) - Mayo Clinic, accessed June 4, 2025, https://www.mayoclinic.org/drugs-supplements/diclofenac-topical-application-route/description/drg-20063434
41. Reference ID: 5482946 - accessdata.fda.gov, accessed June 4, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021005s025lbl.pdf
42. www.accessdata.fda.gov, accessed June 4, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020037s031lbl.pdf
43. Diclofenac (ophthalmic route) - Mayo Clinic, accessed June 4, 2025, https://www.mayoclinic.org/drugs-supplements/diclofenac-ophthalmic-route/description/drg-20074914
44. Diclofenac 1% Gel - Summary of Product Characteristics (SmPC) - (emc) | 10950, accessed June 4, 2025, https://www.medicines.org.uk/emc/product/10950/smpc
45. Diclofenac: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed June 4, 2025, https://www.rxlist.com/diclofenac/generic-drug.htm
46. Diclofenac Uses, Dosage & Side Effects - Drugs.com, accessed June 4, 2025, https://www.drugs.com/diclofenac.html
47. What's the Typical Diclofenac Dosage? Your GoodRx Guide, accessed June 4, 2025, https://www.goodrx.com/diclofenac-sodium/dosage
48. Diclofenac sodium - FDA Verification Portal, accessed June 4, 2025, https://verification.fda.gov.ph/files/DR-XY27795_PI_01.pdf
49. VOLTAREN (diclofenac sodium) SUMMARY OF PRODUCT CHARACTERISTICS - Medicines Authority, accessed June 4, 2025, https://medicinesauthority.gov.mt/file.ashx?f=139DCEC6F67022413E67A03D4458CBABE1DEF85DB2DBD15C
50. Diclofenac: Side Effects, Dosage, Uses, and More - Healthline, accessed June 4, 2025, https://www.healthline.com/health/diclofenac-topical-gel
51. Dyloject™ (diclofenac sodium) Injection - accessdata.fda.gov, accessed June 4, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022396lbl.pdf
52. www.pfizermedicalinformation.com, accessed June 4, 2025, https://www.pfizermedicalinformation.com/arthrotec/drug-interactions#:~:text=Diclofenac%20and%20anticoagulants%20such%20as,use%20of%20either%20drug%20alone.
53. Diclofenac and warfarin Interactions - Drugs.com, accessed June 4, 2025, https://www.drugs.com/drug-interactions/diclofenac-with-warfarin-869-0-2311-0.html
54. Side Effects of Voltaren (diclofenac): Interactions & Warnings - MedicineNet, accessed June 4, 2025, https://www.medicinenet.com/side_effects_of_diclofenac/side-effects.htm
55. www.goodrx.com, accessed June 4, 2025, https://www.goodrx.com/voltaren/interactions#:~:text=As%20discussed%20above%2C%20diclofenac%20also,after%20having%20a%20heart%20attack.
56. Voltaren (Diclofenac Sodium): Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed June 4, 2025, https://www.rxlist.com/voltaren-drug.htm
57. Drug Interaction Report: cortisone, diclofenac - Drugs.com, accessed June 4, 2025, https://www.drugs.com/interactions-check.php?drug_list=748-0,869-0&professional=1
58. Cortisone and diclofenac Interactions - Drugs.com, accessed June 4, 2025, https://www.drugs.com/drug-interactions/cortisone-with-diclofenac-748-0-869-0.html?professional=1
59. NSAIDs and blood pressure medicines | Healthify, accessed June 4, 2025, https://healthify.nz/medicines-a-z/n/nsaids-and-blood-pressure-medicines
60. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study, accessed June 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3541472/
61. www.medicalnewstoday.com, accessed June 4, 2025, https://www.medicalnewstoday.com/articles/drugs-diclofenac-tablets-interactions
62. www.drugs.com, accessed June 4, 2025, https://www.drugs.com/drug-interactions/diclofenac-with-sertraline-869-0-2057-0.html?professional=1#:~:text=diclofenac%20sertraline,-Applies%20to%3A%20diclofenac&text=Published%20case%20reports%20have%20documented,petechiae%20to%20life%2Dthreatening%20hemorrhages.
63. Drug Interactions between diclofenac and sertraline - Drugs.com, accessed June 4, 2025, https://www.drugs.com/drug-interactions/diclofenac-with-sertraline-869-0-2057-0.html?professional=1
64. Diclofenac - LiverTox - NCBI Bookshelf, accessed June 4, 2025, https://www.ncbi.nlm.nih.gov/books/NBK547953/
65. Does diclofenac contain narcotics or affect a drug test? - Drugs.com, accessed June 4, 2025, https://www.drugs.com/medical-answers/does-the-drug-diclofenac-have-narcotics-in-it-179814/
66. Diclofenac - MotherToBaby, accessed June 4, 2025, https://mothertobaby.org/fact-sheets/diclofenac/
67. Solaraze: Package Insert / Prescribing Information - Drugs.com, accessed June 4, 2025, https://www.drugs.com/pro/solaraze.html
68. Diclofenac and Misoprostol: MedlinePlus Drug Information, accessed June 4, 2025, https://medlineplus.gov/druginfo/meds/a699002.html
69. Pregnancy, breastfeeding and fertility while taking or using diclofenac - NHS, accessed June 4, 2025, https://www.nhs.uk/medicines/diclofenac/pregnancy-breastfeeding-and-fertility-while-taking-or-using-diclofenac/
70. Using NSAIDS during breastfeeding – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice, accessed June 4, 2025, https://www.sps.nhs.uk/articles/using-nsaids-during-breastfeeding/
71. Who can and cannot take or use diclofenac - NHS, accessed June 4, 2025, https://www.nhs.uk/medicines/diclofenac/who-can-and-cannot-take-or-use-diclofenac/
72. At what age can pediatric patients be given diclofenac (Nonsteroidal Anti-Inflammatory Drug, NSAID)? - Dr.Oracle AI, accessed June 4, 2025, https://www.droracle.ai/articles/36663/age-of-pediatric-to-be-given-diclofenac
73. Flector Patch (Diclofenac Epolamine Topical Patch): Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed June 4, 2025, https://www.rxlist.com/flector-patch-drug.htm
74. Diclofenac - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction, Renal Dose, Hepatic Dose | Drug Index | Pediatric Oncall, accessed June 4, 2025, https://www.pediatriconcall.com/drugs/diclofenac/486
75. Diclofenac for acute postoperative pain in children - PubMed Central, accessed June 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8992928/
76. TRADENAME(S) Cataflam DESCRIPTION AND COMPOSITION Pharmaceutical form EXCIPIENTS INDICATIONS - Novartis, accessed June 4, 2025, https://www.novartis.com/sg-en/sites/novartis_sg/files/Cataflam-May2019.SINv1-App120821.pdf
77. Label: Voltaren- diclofenac sodium gel - DailyMed, accessed June 4, 2025, https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9d6cf386-7fa1-433d-8fe9-4aa3617ba0e1
78. Reference ID: 3615450 This label may not be the latest approved by FDA. For current labeling information, please visit https://, accessed June 4, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204592s002s004lbl.pdf
79. 204592Orig1s002 | FDA, accessed June 4, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204592Orig1s002.pdf
80. Drug Approval Package: Voltaren (Diclofenac Sodium) NDA #019201 - accessdata.fda.gov, accessed June 4, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/19-201s018_Voltaren.cfm
81. Voltaren Gel (diclofenac sodium) FDA Approval History - Drugs.com, accessed June 4, 2025, https://www.drugs.com/history/voltaren-gel.html
82. www.nhs.uk, accessed June 4, 2025, https://www.nhs.uk/medicines/diclofenac/#:~:text=Diclofenac%20Brand%20names%3A%20Voltarol%2C%20Dicloflex%2C%20Diclomax%2C%20Econac%2C%20Motifene
83. Diclofenac: a medicine to treat pain and swelling - NHS, accessed June 4, 2025, https://www.nhs.uk/medicines/diclofenac/
84. Diclofenac - Hong Kong - OT&P Healthcare, accessed June 4, 2025, https://www.otandp.com/medicines-in-hong-kong/diclofenac
85. Diclofenac Sodium Injection – Manufacturer - AdvaCare Pharma, accessed June 4, 2025, https://www.advacarepharma.com/en/pharmaceuticals/diclofenac-sodium-injection
86. Diclofenac Sodium Manufacturer - CAS 15307-79-6 - Elam Pharma, accessed June 4, 2025, https://www.elampharma.com/product/diclofenac-sodium-ip-bp
87. Diclofenac: MedlinePlus Drug Information, accessed June 4, 2025, https://medlineplus.gov/druginfo/meds/a689002.html
88. Diclofenac sodium overdose Information | Mount Sinai - New York, accessed June 4, 2025, https://www.mountsinai.org/health-library/poison/diclofenac-sodium-overdose